<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183194</url>
  </required_header>
  <id_info>
    <org_study_id>CL0021-01</org_study_id>
    <nct_id>NCT02183194</nct_id>
  </id_info>
  <brief_title>Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>A Prospective, MultiCenter, Single-arm, Post-market Study of Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts (ACCESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Lutonix® 035 Drug Coated Balloon PTA Catheter
      (CE mark) for use as intended in the treatment of subjects with clinically significant
      hemodialysis vascular access stenosis or occlusion.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>Target Lesion Primary Patency (TLPP): The interval following index procedure intervention until the next reintervention of the target lesion or access thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Primary Patency (TLPP)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access circuit primary patency</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abandonment of permanent access in the index extremity</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions required to maintain target lesion patency</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interventions, required to maintain access circuit patency</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The access circuit is defined as &quot;the area from the AV access graft arterial anastomosis to the superior vena-cava right atrial junction.&quot; The outcome is recording all interventions that occur in the access circuit up until the time of circuit failure (patency).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>&lt; or at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device and procedure related adverse events</measure>
    <time_frame>1, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dysfunctional AV Graft</condition>
  <condition>Dysfunctional AV Fistula</condition>
  <arm_group>
    <arm_group_label>Lutonix Paclitaxel Drug Coated Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Paclitaxel Drug Coated Balloon</intervention_name>
    <arm_group_label>Lutonix Paclitaxel Drug Coated Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. The subject is legally competent, has been informed of the nature, the scope and the
             relevance of the study, voluntarily agrees to participation and the study's
             provisions, and has duly signed the informed consent form (ICF)

          3. Hemodialysis access on the arm presenting with any clinical abnormalities as defined
             in the K/DOQI guidelines

          4. Native AV fistula or synthetic AV graft has been implanted ≥30 days

          5. Target de novo or non-stented restenotic lesion(s) consisting of a &gt;50% stenosis by
             visual estimate. Successful treatment of non target lesion(s) (residual stenosis &lt;30%
             by visual estimate) without procedural complication by standard of care

          6. Successful predilatation of the target lesion with a percutaneous transluminal
             angioplasty (PTA) balloon

          7. Intended target lesion(s) (maximum of 2) can be treated

          8. No other prior surgical or vascular interventions within 2 weeks before and/or planned
             30 days after the treatment

        Exclusion Criteria:

          1. Women who are pregnant, lactating, or planning on becoming pregnant or men intending
             to father children

          2. Known contraindication (including allergic reaction) or sensitivity to contrast media,
             ASA, clopidogrel, ticlopidine, paclitaxel (mild to severe cases), that cannot be
             adequately managed with pre-and post-procedure medication

          3. Life expectancy &lt;12months

          4. Scheduled for kidney transplant or peritoneal dialysis in the next 12months;

          5. Thrombosed access

          6. Stent in the target treatment area

          7. Blood coagulative disorder, sepsis, or current AV access infection

          8. Currently participating in an investigational drug, biologic, or device study, or
             previous enrollment in this study NOTE: Enrollment in another investigational drug,
             biologic, or device study during the follow- up period is not allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln AöR</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein - Campus Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

